DaewonPharmaceutical Develops ‘Felubi’ as a Pediatric Antipyretic… Phase 2 Clinical Trial Approved
Study Involving 60 Patients Aged 2 to 12 with Fever… Evaluating Antipyretic Efficacy and Safety
Domestic New Drug No. 12 Approaches Its 20th Anniversary Since Approval… Expanding from Tablets to Syrup Formulation
[Edaily Reporter NA EUN-KYUNG ] DaewonPharmaceutical(003220)Daewon Pharmaceutical is embarking on the development of a pediatric antipyretic based on “Felubi,” Korea’s 12th domestically developed new drug. This comes approximately 20 years after Felubi was approved as an anti-inflammatory analgesic for adults in 2007.
DaewonPharmaceutical announced on the 16th that it had received approval from the Ministry of Food and Drug Safety for its Phase 2 clinical trial plan (IND) for “DW5524,” a pediatric syrup formulation utilizing felubipropen, the active ingredient in Felubi.
DW5524 is a liquid formulation developed for pediatric patients who have difficulty swallowing tablets. Since felubipropen is a poorly water-soluble substance, DaewonPharmaceutical developed the formulation using a suspension method that evenly disperses the active ingredient in the liquid. The company expects this formulation to improve ease of administration and enhance the rate of drug absorption compared to existing tablets.
This clinical trial will enroll 60 patients aged 2 to 12 years who have a fever due to acute upper respiratory tract infection. Patients will be divided into a low-dose DW5524 group, a high-dose DW5524 group, and an active control group to compare the extent to which body temperature decreases four hours after drug administration. The trial will also examine the rate at which body temperature returns to normal, the time required for this to occur, and any adverse events.
Another key feature is that the trial will be conducted in phases based on the patients’ ages. The company plans to first administer the drug to patients aged 6 to 12, review the results regarding efficacy, safety, and pharmacokinetic analysis, and then expand the trial to include patients aged 2 to under 6. The expected trial period, as registered with the National Clinical Trial Support Foundation, is from December of this year through December 2028.
DaewonPharmaceutical received approval for its Phase 1 clinical trial plan for adults in December of last year and completed the trial in February of this year. At that time, the company verified the drug’s characteristics across different doses—6 mL, 12 mL, and 18 mL—and, based on these findings, conducted pharmacokinetic and pharmacodynamic (PK/PD) modeling to determine the dosage to be used in the pediatric clinical trial.
Felubi is a nonsteroidal anti-inflammatory drug (NSAID) that was approved in April 2007. Initially launched as a treatment for osteoarthritis, its indications were expanded to include rheumatoid arthritis and low back pain, and in 2017, it was approved for the treatment of fever associated with acute upper respiratory tract infections. In a Phase 3 clinical trial conducted at that time on adult patients with fever, both the felubipropen and loxoprofen groups showed a 1.68-degree decrease in average body temperature after 4 hours, confirming the non-inferiority of their antipyretic effects. However, the appropriate dosage, antipyretic efficacy, and safety in pediatric patients must be separately verified in this clinical trial.
Felubi is one of DaewonPharmaceutical’s major prescription drugs. According to Ubist, a pharmaceutical market research firm, the 2024 outpatient prescription sales for Felubi Tablets and Felubi Extended-Release Tablets totaled 62.2 billion won. The company has since expanded its product line by launching “Felubi ES Tablets,” which incorporate a new salt formulation.
This study on the pediatric syrup formulation is being conducted as part of the “Research and Development Project to Overcome Pediatric Diseases,” supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. DaewonPharmaceutical is leading the research, with Chungbuk National University Hospital and Gyeongsang National University Hospital participating. The company aims to secure approval for a Phase 3 clinical trial following the completion of the Phase 2 trial.
A DaewonPharmaceutical official stated, “Based on our accumulated research experience, we will thoroughly evaluate the antipyretic efficacy and safety in pediatric patients and continue development to provide a new treatment option for pediatric fever.” DaewonPharmaceutical CI (Photo courtesy of DaewonPharmaceutical)
LG Energy Solution delivered encouragement gifts to the children of its employees ahead of the 2027 College Scholastic Ability Test.
LG Energy Solution’s 2027 College Scholastic Ability Test gift p…
○ Executive-Level Promotions at Lotte Group Affiliates◇CEO△Seo Jeong-ho, President and CEO of LOTTE WELLFOOD△Shin Yu-yeol, Head of the Future Growth Division at Lotte Corporation and President and CEO…
DaewonPharmaceutical(003220)Daewon Pharmaceutical is embarking on the development of a pediatric antipyretic based on “Felubi,” Korea’s 12th domestically developed new drug. This comes approximately 2…